Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

TBD

DOI: 10.1111/bjd.16156

---

• What is this paper about?

  Dupilumab with topical steroids significantly improved eczema symptoms in adults who couldn't use or didn't respond to ciclosporin A, with about 60% of patients showing major improvement compared to 30% on placebo.

• How did the authors study this?

  Study was conducted through a randomized controlled trial (RCT). RCTs are considered the gold standard for drawing evidence-based conclusions.

• What populations did the authors study?

  Adults with atopic dermatitis with inadequate response to/intolerance of ciclosporin A, or for whom ciclosporin A treatment was medically inadvisable

• What did the authors find?

  EASI-75: Percentage of patients achieving 75% or greater improvement in Eczema Area and Severity Index